Sujata Patil

Sujata Patil

Auto-generated profile, based on publicly available information

Sujata Patil

Department of Quantitative Health Sciences, Cleveland Clinic

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
EZEmily C. Zabor
Emily C. Zabor
CRChandana A. Reddy
Chandana A. Reddy
RTRahul D. Tendulkar
Rahul D. Tendulkar
SPSujata Patil
Sujata Patil

14 July 2014 in Clinical Cancer Research
Verified
Journal Article
Closed access
DFDarren R Feldman
Darren R Feldman
GIGopa Iyer
Gopa Iyer
LALindsay Van Alstine
Lindsay Van Alstine
SPSujata Patil
Sujata Patil
HAHikmat A. Al-Ahmadie
Hikmat A. Al-Ahmadie
DSDavid B. Solit
David B. Solit
Purpose: A previous study noted frequent B-RAF mutations among European patients with cisplatin-resistant but not cisplatin-sensitive germ cell tumors (GCT). We sought to validate this finding by assessing for these mutations among patients with GCT at our center. Experimental Design: Adolescent and adult patients with GCT who received cisplatin-based chemotherapy and had tumor tissue available were eligible for participation. Response to cisplatin was reviewed to determine sensitivity and resistance. Tumor DNA was extracted and subjected to Sequenom analysis to detect hotspot alterations in FGFR3, AKT1, PIK3CA, KRAS, HRAS, NRAS, and BRAF with Sanger sequencing for confirmation. Nine GCT cell lines with varying degrees of cisplatin sensitivity and resistance were also assayed by Sequenom. Results: Seventy (24 cisplatin-sensitive; 46 cisplatin-resistant) of 75 patients had tumors with sufficient quality DNA to perform Sequenom. Nineteen mutations were detected among 16 (23%) patients but no BRAF mutations were identified. Similarly, none of the cell lines harbored BRAF mutations. FGFR3 was the most frequent mutation, identified in 13% of both sensitive and resistant samples. All other mutations were exclusive to resistant cases (3 KRAS, 3 AKT1, 3 PIK3CA, and 1 HRAS). Conclusions:BRAF mutations are rare in American patients with GCT, including those with cisplatin resistance. However, other potentially targetable mutations occur in more than 25% of cisplatin-resistant patients. FGFR3, AKT1, and PIK3CA mutations are all reported for the first time in GCT. Whereas FGFR3 mutations occurred with equal frequency in both sensitive and resistant GCTs, mutations in AKT1 and PIK3CA were observed exclusively in cisplatin-resistant tumors. Clin Cancer Res; 20(14); 3712–20. ©2014 AACR.

3 October 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
YGYasser Ged
Yasser Ged
ASAlejandro Sanchez
Alejandro Sanchez
SPSujata Patil
Sujata Patil
AKAndrea Knezevic
Andrea Knezevic
ESEmily Stein
Emily Stein
Helena FurbergHelena Furberg
Helena Furberg
Purpose: High body mass index (BMI) may lead to improved immune-checkpoint blockade (ICB) outcomes in metastatic clear cell renal cell carcinoma (mccRCC). However, BMI is a crude body size measure. We investigated BMI and radiographically assessed body composition (BC) parameters association with mccRCC ICB outcomes. Experimental Design: Retrospective study of ICB-treated patients with mccRCC. BMI and BC variables [skeletal muscle index (SMI) and multiple adiposity indexes] were determined using pretreatment CT scans. We examined the associations between BMI and BC variables with ICB outcomes. Therapeutic responses per RECIST v1.1 were determined. We compared whole-transcriptomic patterns with BC variables in a separate cohort of 62 primary tumor samples. Results: 205 patients with mccRCC were included in the cohort (74% were male, 71% were overweight/obese, and 53% were classified as low SMI). High-BMI patients experienced longer overall survival (OS) than normal-weight patients [unadjusted HR, 0.66; 95% confidence interval (CI), 0.45–0.97; P = 0.035]. The only BC variable associated with OS was SMI [unadjusted HR comparing low vs. high SMI 1.65 (95% CI: 1.13–2.43); P = 0.009]. However, this OS association became nonsignificant after adjusting for International Metastatic Renal Cell Carcinoma Database Consortium score and line of therapy. No OS association was seen for adiposity and no BC variable was associated with progression-free survival or radiological responses. Tumors from patients with low SMI displayed increased angiogenic, inflammatory, and myeloid signals. Conclusions: Our findings highlight the relevance of skeletal muscle in the BMI paradox. Future studies should investigate if addressing low skeletal muscle in metastatic patients treated with ICB can improve survival.

10 September 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JGJack Patrick Gleeson
Jack Patrick Gleeson
AKAndrea Knezevic
Andrea Knezevic
MBMaria Bromberg
Maria Bromberg
SPSujata Patil
Sujata Patil
JSJoel Sheinfeld
Joel Sheinfeld
DFDarren R Feldman
Darren R Feldman
PURPOSE: Paclitaxel, ifosfamide, and cisplatin (TIP) is an established salvage regimen for germ cell tumors (GCT) on the basis of a phase II trial, but efficacy on a large patient cohort including patients with unfavorable risk features and long-term outcomes has not been reported. Herein, we report updated treatment efficacy and long-term follow-up with TIP. PATIENTS AND METHODS: Patients with GCT who received TIP after cisplatin-based chemotherapy were eligible. Favorable response (complete response or partial response with negative tumor markers), overall survival (OS) and progression-free survival (PFS) rates, relapse, and toxicity were determined. Disease was reclassified according to the International Prognostic Factor Study Group (IPFSG) score. RESULTS: Of the 104 patients, 87 had favorable risk factors and 17 had at least one unfavorable factor by Memorial Sloan Kettering Cancer Center (MSKCC) criteria. Ten patients were treated for a second gonadal primary GCT. With a median follow-up of 8.9 years, the 5-year PFS and OS rates were 66% (95% CI, 55 to 74) and 69% (95% CI, 59 to 77), respectively. Among 87 patients with favorable-risk disease, 69 (79%) achieved a favorable response with 5-year PFS and OS rates of 67% (95% CI, 56 to 76) and 72% (95% CI, 61 to 80), respectively. Among 17 patients with MSKCC unfavorable-risk disease, 13 (76%) achieved a favorable response with 5-year PFS and OS rates of 59% (95% CI, 33 to 78) and 56% (95% CI, 28 to 76), respectively. After IPFSG reclassification, 5-year PFS and OS rates for patients with ≤intermediate-risk disease were 75% (95% CI, 50 to 89) and 73% (95% CI, 55 to 85), respectively. CONCLUSION: TIP is an effective second-line regimen for patients with GCT. Similar outcomes were observed in patients with favorable- and unfavorable-risk disease. The randomized TIGER trial (ClinicalTrials.gov identifier: NCT02375204 ) comparing TIP with high-dose chemotherapy will determine the optimal second-line treatment approach.

20 January 2023 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
ACAngelena Crown
Angelena Crown
DMDamian McCartan
Damian McCartan
MCMichael A. Curry
Michael A. Curry
SPSujata Patil
Sujata Patil
SKSabrina Kamer
Sabrina Kamer
MGMary L. Gemignani
Mary L. Gemignani

7 August 2025 in Statistics in Medicine
Verified
Journal Article
Open access
JMJunhui Mi
Junhui Mi
RTRahul D. Tendulkar
Rahul D. Tendulkar
SSSarah M. C. Sittenfeld
Sarah M. C. Sittenfeld
SPSujata Patil
Sujata Patil
EZEmily C. Zabor
Emily C. Zabor
Methods to handle missing data have been extensively explored in the context of estimation and descriptive studies, with multiple imputation being the most widely used method in clinical research. However, in the context of clinical risk prediction models, where the goal is often to achieve high prediction accuracy and to make predictions for future patients, there are different considerations regarding the handling of missing covariate data. As a result, deterministic imputation is better suited to the setting of clinical risk prediction models, since the outcome is not included in the imputation model and the imputation method can be easily applied to future patients. In this paper, we provide a tutorial demonstrating how to conduct bootstrapping followed by deterministic imputation of missing covariate data to construct and internally validate the performance of a clinical risk prediction model in the presence of missing data. Simulation study results are provided to help guide when imputation may be appropriate in real‐world applications.